Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage II... von Yoshioka, H., Shimokawa, M., Seto, T., Morita, S., Yatabe, Y., Okamoto, I., Tsurutani, J., Satouchi, M., Hirashima, T., Atagi, S., Shibata, K., Saito, H., Toyooka, S., Yamamoto, N., Nakagawa, K., Mitsudomi, T.

Volltext

Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01) von Saura, C., Modi, S., Krop, I., Park, Y.H., Kim, S.-B., Tamura, K., Iwata, H., Tsurutani, J., Sohn, J., Mathias, E., Liu, Y., Cathcart, J., Singh, J., Yamashita, T.

Volltext

A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HE... von Sakai, H., Tsurutani, J., Ozaki, Y., Ishiguro, H., Nozawa, K., Yamanaka, T., Aogi, K., Matsumoto, K., Iwasa, T., Tokiwa, M., Tsuneizumi, M., Miyoshi, Y., Kitagawa, C., Yamamoto, M., Takano, Y., Imamura, C.K., Chiba, Y., Takiguchi, D., Ezumi, T., Takano, T.

Volltext

Eribulin as first- or second-line chemotherapy for advanced or metastatic HER2-negative breast cancer: A real-world prospective study von Takahashi, M., Inoue, K., Mukai, H., Yamanaka, T., Egawa, C., Sakata, Y., Ikezawa, H., Matsuoka, T., Tsurutani, J.

Volltext

Updated results of phase I study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer von Yoshino, T, Iwata, H, Tamura, K, Takahashi, S, Redfern, C, Modi, S, Doi, T, Kawakami, H, Taniguchi, H, Takashima, A, Yamaguchi, K, Fisher, J, Li, B, Saito, K, Fujisaki, Y, Sugihara, M, Tsurutani, J

Volltext

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer von Modi, Shanu, Saura, Cristina, Yamashita, Toshinari, Park, Yeon Hee, Kim, Sung-Bae, Tamura, Kenji, Andre, Fabrice, Iwata, Hiroji, Ito, Yoshinori, Tsurutani, Junji, Sohn, Joohyuk, Denduluri, Neelima, Perrin, Christophe, Aogi, Kenjiro, Tokunaga, Eriko, Im, Seock-Ah, Lee, Keun Seok, Hurvitz, Sara A, Cortes, Javier, Lee, Caleb, Chen, Shuquan, Zhang, Lin, Shahidi, Javad, Yver, Antoine, Krop, Ian

Volltext

A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer von Sakiyama, T, Tsurutani, J, Iwasa, T, Kawakami, H, Nonagase, Y, Yoshida, T, Tanaka, K, Fujisaka, Y, Kurata, T, Komoike, Y, Nishio, K, Nakagawa, K

Volltext

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC von Takeda, Masayuki, Okamoto, Isamu, Tsurutani, Junji, Oiso, Naoki, Kawada, Akira, Nakagawa, Kazuhiko

Volltext

2152 Exploratory analysis of predictive biomarkers of oxaliplatin versus irinotecan in combination with bevacizumab for patients with metastatic colorectal cancer in WJOG4407G stud... von Fujita, Y, Yamazaki, K, Oba, M.S, Muro, K, Negoro, Y, Yoshida, M, Suyama, K, Kurimoto, T, Sugimoto, N, Seki, N, Sato, M, Ebi, M, Tamagawa, H, Ueda, S, Tamura, T, Boku, N, Hyodo, I, Yamanaka, T, Tsurutani, J, Nishio, K

Volltext

2168 Predictive biomarker analysis of early tumor shrinkage induced by FOLFIRI+Bev for patients with metastatic colorectal cancer in WJOG4407G study von Tsuji, Y, Yamazaki, K, Oba, M. Saito, Sakai, K, Nagase, M, Ueda, S, Tamagawa, H, Tamura, T, Moriwaki, T, Murata, K, Taira, K, Denda, T, Funai, S, Tsuda, T, Tsushima, T, Boku, N, Hyodo, I, Yamanaka, T, Tsurutani, J, Nishio, K

Volltext

1478P Dual single-nucleotide polymorphism biomarker combination to select opioid for cancer pain management von Fujita, Y., Matsuoka, H., Tsurutani, J., Yoshida, T., Koyama, A., Nishio, K., Nakagawa, K.

Volltext

Zoledronic acid-induced regression of multiple metastases at nonskeletal sites von Okamoto, K., Tsurutani, J., Terashima, M., Okamoto, I., Nakagawa, K.

Volltext

Evaluation of Two Phosphorylation Sites Improves the Prognostic Significance of Akt Activation in Non–Small-Cell Lung Cancer Tumors von TSURUTANI, Junji, FUKUOKA, Junya, TSURUTANI, Hiroko, SHIH, Joanna H, HEWITT, Stephen M, TRAVIS, William D, JIN JEN, DENNIS, Phillip A

Volltext

PS3-1 Dato-DXd vs. chemotherapy for patients with inoperable/metastatic HR+/HER2− breast cancer: TROPION-Breast01 Asian subset von Tsurutani, J., Hattori, M., Im, S., Wang, S., Lu, Y., Sohn, J., Zhang, Q., Park, Y., Lee, K., Ozaki, Y., Jiang, Z., Chung, W., De Laurentiis, M., Pernas, S., Xu, L., Khan, S., Denduluri, N., Pistilli, B., Bardia, A., Xu, B.

Volltext

LBA22 Effects of trastuzumab deruxtecan (T-DXd) vs choice of chemotherapy (TPC) on patient-reported outcomes (PROs) in hormone receptor-positive, HER2-low or HER2-ultralow metastat... von Hu, X., Curigliano, G., Yonemori, K., Bardia, A., Barrios, C.H.E., Sohn, J., Levy, C., Jacot, W., Tsurutani, J., Mezei, K., Roborel de Climens, A., Wu, X., Begbie, N., Mbanya, Z., Dent, R.A.

Volltext

LBA21 Human epidermal growth factor receptor 2 (HER2)-low and HER2-ultralow status determination in tumors of patients (pts) with hormone receptor–positive (HR+) metastatic breast... von Salgado, R.F., Bardia, A., Curigliano, G., Hu, X., Dent, R.A., Pierga, J-Y., Tsurutani, J., Wildiers, H., Ricciardi, G.R.R., Marchiò, C., Penault-Llorca, F., Bor-Angelier, C., Andrzejuk-Cwik, A., Darilay, A., Matsuo, T., Shami, R., Jones, F., Viale, G.

Volltext

O5-2 WJOG (West Japan Oncology Group) Breast Cancer Consensus Meeting 2023 von Kimura, Y., Watanuki, R., Aoyama, Y., Sakai, H., Shimomura, A., Tsurutani, J., Tokunaga, S., Mukohara, T., Matsumoto, K., Iwasa, T., Ozaki, Y., Nozawa, K., Terada, M., Kizawa, R., Takano, T.

Volltext

373P Quality-of-life outcomes in patients with HER2-positive, locally advanced or metastatic breast cancer treated with eribulin mesylate in combination with trastuzumab and pertuz... von Masuda, N., Saji, S., Iwatani, T., Takano, T., Koizumi, K., Sagara, Y., Naito, Y., Tsuneizumi, M., Yoshimura, A., Takahashi, M., Tsurutani, J., Kitada, M., Tada, H., Higuchi, T., Kojima, Y., Kadoya, T., Hasegawa, H., Uchida, Y., Morita, S., Yamashita, T.

Volltext

1816O A multicentre, randomized, double-blind, placebo-controlled study of olanzapine-based triplet antiemetic therapy for prevention of delayed and persistent nausea and vomiting... von Sakai, H., Tsurutani, J., Ozaki, Y., Ishiguro, H., Nozawa, K., Yamanaka, T., Kameoka, H., Matsumoto, K., Iwasa, T., Tokiwa, M., Tsuneizumi, M., Miyoshi, Y., Kitagawa, C., Yamamoto, M., Takano, Y., Imamura, C.K., Chiba, Y., Takiguchi, D., Ezumi, T., Takano, T.

Volltext

Trastuzumab Deruxtecan in Previously Treated Patients With HER2-Positive Metastatic Breast Cancer: Updated Survival Results From a Phase 2 Trial (DESTINY-Breast01) von Saura, C., Modi, S., Krop, I., Park, Y. H., Kim, S-B., Tamura, K., Iwata, H., Tsurutani, J., Sohn, J., Mathias, E., Liu, Y., Cathcart, J., Singh, J., Yamashita, T.

Volltext